<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2182-7230</journal-id>
<journal-title><![CDATA[Revista Nutrícias]]></journal-title>
<abbrev-journal-title><![CDATA[Nutrícias]]></abbrev-journal-title>
<issn>2182-7230</issn>
<publisher>
<publisher-name><![CDATA[Associação Portuguesa dos Nutricionistas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2182-72302012000300008</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Intervenção nutricional na esclerose lateral amiotrófica - considerações gerais]]></article-title>
<article-title xml:lang="en"><![CDATA[Nutritional intervention in amyotrophic lateral sclerosis - general considerations]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Reis]]></surname>
<given-names><![CDATA[Cíntia]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pinto]]></surname>
<given-names><![CDATA[Isabel]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Universidade Católica Portuguesa Escola Superior de Biotecnologia ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A02">
<institution><![CDATA[,Unidade Local de Saúde de Matosinhos, E.P.E. Serviço de Nutrição e Alimentação ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2012</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2012</year>
</pub-date>
<numero>14</numero>
<fpage>31</fpage>
<lpage>34</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S2182-72302012000300008&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S2182-72302012000300008&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S2182-72302012000300008&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[A Esclerose Lateral Amiotrófica (ELA) (também designada por Doença de Lou Gehrig, Doença de Charcot e Doença do Neurónio Motor) é uma doença neurodegenerativa caracterizada pela degeneração selectiva dos neurónios motores superiores e inferiores do cortéx motor primário, do tronco cerebral, da espinal medula e do tracto corticoespinhal, originando a paralisia muscular progressiva de todos os membros do corpo, falência respiratória e morte entre 3 a 5 anos após o início dos sintomas. Na ELA a intervenção nutricional deverá maximizar o conforto do doente, pelo que deve ser planeada e adaptada de acordo com o processo evolutivo da doença. Como consequência da progressão da doença, a disfagia emerge como um dos sintomas que mais interferirá com a alimentação habitual dos doentes. Inicialmente, o controlo da disfagia exigirá uma intervenção nutricional personalizada que vise a adaptação da consistência da dieta à capacidade deglutiva do doente. Posteriormente, o agravamento da disfagia exigirá a mudança da via alimentar e consequente adaptação do doente a um novo método de administração da dieta e a um novo tipo de dieta. Do mesmo modo, sendo a ELA uma doença incapacitante e que progride sem possibilidade de cura é fundamental que o nutricionista interprete o significado que as alterações alimentares representam para o doente e a sua família, com o objectivo de promover a qualidade de vida do doente e assistir a família em todas as questões e dificuldades relacionadas com a alimentação do seu ente querido. Assim, pretende-se discutir o papel da nutrição na ELA não só no que diz respeito à importância e ao planeamento da intervenção nutricional, ao controlo da disfagia e ao suporte nutricional entérico mas também à abordagem centrada no doente e na sua família e que poderá influenciar a intervenção nutricional junto desta população.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Amyotrophic Lateral Sclerosis (ALS) (also known as Lou Gehrig's Disease, Charcot's Disease and Motor Neurone Disease) is a neurodegenerative disease characterized by selective degeneration of upper and lower motor neurons in the primary motor cortex, brainstem, spinal cord and corticospinal tract, which results in progressive muscular paralysis of all limbs, respiratory failure and death within 3-5 years after the onset of symptoms. ALS´ nutritional intervention should maximize patient comfort, so that it should be planned and adapted according to the disease progression. As a consequence of disease progression, dysphagia emerges as the symptom that will interfere most in patients´ usual feeding. Initially, dysphagia management requires a personalized nutritional intervention focused on adapting food consistency to the swallowing capacity of the patient. As dysphagia increases a change in the feeding route will be needed and consequently patients will have to adapt to a new feeding method and a new type of diet. Similarly, being ALS an incapacitating and progressive disease with no known cure it is essential for the nutritionist to interpret the meaning of feeding changes to the patient and family. The goal is to promote patient&#8217;s quality of life and support family on all issues and difficulties related to feeding their loved one. Thus, we intend to discuss the role of nutrition in ALS not only regarding to the importance and planning of nutritional intervention, dysphagia management and enteral nutritional support but also to the nutritional approach focused on the patient and family which can influence the nutritional intervention in this population.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Esclerose Lateral Amiotrófica]]></kwd>
<kwd lng="pt"><![CDATA[Intervenção nutricional]]></kwd>
<kwd lng="pt"><![CDATA[Disfagia]]></kwd>
<kwd lng="pt"><![CDATA[Alimentação oral]]></kwd>
<kwd lng="pt"><![CDATA[Nutrição entérica]]></kwd>
<kwd lng="en"><![CDATA[Amyotrophic Lateral Sclerosis]]></kwd>
<kwd lng="en"><![CDATA[Nutritional intervention]]></kwd>
<kwd lng="en"><![CDATA[Dysphagia]]></kwd>
<kwd lng="en"><![CDATA[Oral feeding]]></kwd>
<kwd lng="en"><![CDATA[Enteral nutrition]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p align="right"><b>ARTIGO DE REVIS&#195;O</b></p>     <p><b >Interven&#231;&#227;o nutricional na esclerose lateral amiotr&#243;fica &#8211; considera&#231;&#245;es gerais</b>    <p>     <p><b >Nutritional intervention in amyotrophic lateral sclerosis &#8211; general considerations</b></p>     <p>&nbsp;</p>     <p ><b>C&#237;ntia Reis<sup>1</sup>; Isabel Pinto<sup>2</sup></b></p>     <p><sup>1</sup> Estagi&#225;ria de Ci&#234;ncias da Nutri&#231;&#227;o, Escola Superior de Biotecnologia da Universidade Cat&#243;lica Portuguesa <br/><sup>2</sup> Nutricionista, Servi&#231;o de Nutri&#231;&#227;o e Alimenta&#231;&#227;o, Unidade Local de Sa&#250;de de Matosinhos, E.P.E.</p>     <p><b ><a href="#c0">Endere&#231;o para correspond&#234;ncia</a><a name="topc0"></a></b></p>     <p>&nbsp;</p>     <p><b >RESUMO</b></p>     ]]></body>
<body><![CDATA[<p>A Esclerose Lateral Amiotr&#243;fica (ELA) (tamb&#233;m designada por Doen&#231;a de Lou Gehrig, Doen&#231;a de Charcot e Doen&#231;a do Neur&#243;nio Motor) &#233; uma doen&#231;a neurodegenerativa caracterizada pela degenera&#231;&#227;o selectiva dos neur&#243;nios motores superiores e inferiores do cort&#233;x motor prim&#225;rio, do tronco cerebral, da espinal medula e do tracto corticoespinhal, originando a paralisia muscular progressiva de todos os membros do corpo, fal&#234;ncia respirat&#243;ria e morte entre 3 a 5 anos ap&#243;s o in&#237;cio dos sintomas. <br/>Na ELA a interven&#231;&#227;o nutricional dever&#225; maximizar o conforto do doente, pelo que deve ser planeada e adaptada de acordo com o processo evolutivo da doen&#231;a. Como consequ&#234;ncia da progress&#227;o da doen&#231;a, a disfagia emerge como um dos sintomas que mais interferir&#225; com a alimenta&#231;&#227;o habitual dos doentes. Inicialmente, o controlo da disfagia exigir&#225; uma interven&#231;&#227;o nutricional personalizada que vise a adapta&#231;&#227;o da consist&#234;ncia da dieta &#224; capacidade deglutiva do doente. Posteriormente, o agravamento da disfagia exigir&#225; a mudan&#231;a da via alimentar e consequente adapta&#231;&#227;o do doente a um novo m&#233;todo de administra&#231;&#227;o da dieta e a um novo tipo de dieta. Do mesmo modo, sendo a ELA uma doen&#231;a incapacitante e que progride sem possibilidade de cura &#233; fundamental que o nutricionista interprete o significado que as altera&#231;&#245;es alimentares representam para o doente e a sua fam&#237;lia, com o objectivo de promover a qualidade de vida do doente e assistir a fam&#237;lia em todas as quest&#245;es e dificuldades relacionadas com a alimenta&#231;&#227;o do seu ente querido. <br/>Assim, pretende-se discutir o papel da nutri&#231;&#227;o na ELA n&#227;o s&#243; no que diz respeito &#224; import&#226;ncia e ao planeamento da interven&#231;&#227;o nutricional, ao controlo da disfagia e ao suporte nutricional ent&#233;rico mas tamb&#233;m &#224; abordagem centrada no doente e na sua fam&#237;lia e que poder&#225; influenciar a interven&#231;&#227;o nutricional junto desta popula&#231;&#227;o.</p>     <p><b >Palavras-Chave:</b> Esclerose Lateral Amiotr&#243;fica, Interven&#231;&#227;o nutricional, Disfagia, Alimenta&#231;&#227;o oral, Nutri&#231;&#227;o ent&#233;rica</p>     <p>&nbsp;</p><hr>    <p>&nbsp;</p>     <p><b >ABSTRACT</b></p>     <p>Amyotrophic Lateral Sclerosis (ALS) (also known as Lou Gehrig's Disease, Charcot's Disease and Motor Neurone Disease) is a neurodegenerative disease characterized by selective degeneration of upper and lower motor neurons in the primary motor cortex, brainstem, spinal cord and corticospinal tract, which results in progressive muscular paralysis of all limbs, respiratory failure and death within 3-5 years after the onset of symptoms. <br/>ALS&#180; nutritional intervention should maximize patient comfort, so that it should be planned and adapted according to the disease progression. As a consequence of disease progression, dysphagia emerges as the symptom that will interfere most in patients&#180; usual feeding. Initially, dysphagia management requires a personalized nutritional intervention focused on adapting food consistency to the swallowing capacity of the patient. As dysphagia increases a change in the feeding route will be needed and consequently patients will have to adapt to a new feeding method and a new type of diet. Similarly, being ALS an incapacitating and progressive disease with no known cure it is essential for the nutritionist to interpret the meaning of feeding changes to the patient and family. The goal is to promote patient&#8217;s quality of life and support family on all issues and difficulties related to feeding their loved one. <br/>Thus, we intend to discuss the role of nutrition in ALS not only regarding to the importance and planning of nutritional intervention, dysphagia management and enteral nutritional support but also to the nutritional approach focused on the patient and family which can influence the nutritional intervention in this population.</p>     <p><b>keywords</b>: Amyotrophic Lateral Sclerosis, Nutritional intervention, Dysphagia, Oral feeding, Enteral nutrition</p>     <p>&nbsp;</p><hr>    <p>&nbsp;</p>     <p><b     ]]></body>
<body><![CDATA[>Introdu&#231;&#227;o</b>     <br/>A     ELA foi referenciada pela primeira vez no s&#233;culo XIX e &#233; actualmente     considerada uma das doen&#231;as neuromusculares mais frequentes no mundo.     Caracteriza-se pela degenera&#231;&#227;o progressiva dos neur&#243;nios motores superiores e     inferiores do cort&#233;x motor prim&#225;rio, do tronco cerebral, da espinal medula e do     tracto corticoespinhal. A doen&#231;a possui quatro poss&#237;veis tipos de in&#237;cio: o     bulbar, o respirat&#243;rio, nos membros superiores ou nos membros inferiores. O     in&#237;cio bulbar caracteriza-se por disartria e mais tarde por disfagia. O in&#237;cio     respirat&#243;rio &#233; o mais raro e manifesta-se atrav&#233;s de insufici&#234;ncia     ]]></body>
<body><![CDATA[respirat&#243;ria. Nos membros superiores, o in&#237;cio da doen&#231;a caracteriza-se por     espasticidade, fraqueza muscular e fascicula&#231;&#245;es enquanto que o in&#237;cio nos     membros inferiores manifesta-se por hiperreflexia e atrofia muscular (1-3).     <br/>Muito     embora a ELA se apresente como uma desordem motora, &#233; actualmente reconhecida     como uma doen&#231;a multi-sistem&#225;tica com envolvimento extra-motor, j&#225; que para     al&#233;m de em fases mais avan&#231;adas acabar por atingir todos os membros do corpo,     poder&#225; afectar indirectamente o estado psicol&#243;gico e emocional do doente (1-6).     <br/>A     etiologia da ELA &#233; ainda pouco clara, pois os mecanismos resultantes na     ]]></body>
<body><![CDATA[degenera&#231;&#227;o dos neur&#243;nios motores s&#227;o complexos e multifactoriais. No entanto,     acredita-se que a interac&#231;&#227;o entre factores end&#243;genos (gen&#233;ticos e metab&#243;licos)     e factores ex&#243;genos (ambientais e de estilos de vida) estejam envolvidos no     desenvolvimento da doen&#231;a (6-11). Assim, a maioria dos casos &#233; espor&#225;dica e     apenas 10% destes parecem estar associados a um historial familiar (1-3,7).      <br/>Dados     epidemiol&#243;gicos indicam que a ELA &#233; mais prevalente nos homens e que o seu     in&#237;cio situa-se, em m&#233;dia, entre os 55-65 anos de idade. A sua incid&#234;ncia     aumenta ap&#243;s os 40 anos, sendo que n&#227;o &#233; comum o seu surgimento ap&#243;s os 70 anos     de idade. A sobrevida mediana &#233; de 3 a 5 anos ap&#243;s in&#237;cio dos primeiros     ]]></body>
<body><![CDATA[sintomas. A principal causa de morte &#233; a fal&#234;ncia respirat&#243;ria (1-3).     <br/>Nos     &#250;ltimos 25 anos v&#225;rios progressos t&#234;m sido feitos no sentido de proporcionar     cuidados que melhorem a qualidade de vida do doente (1). No entanto, pelas suas     caracter&#237;sticas cl&#237;nicas, o tratamento da ELA &#233; complexo pois requer n&#227;o s&#243; a     gest&#227;o de m&#250;ltiplos sintomas f&#237;sicos mas tamb&#233;m emocionais ao longo da     progress&#227;o da doen&#231;a. Por este motivo &#233; recomendada uma abordagem     multidisciplinar, onde o nutricionista desempenha um papel importante no     suporte e acompanhamento das altera&#231;&#245;es alimentares decorrentes do processo     evolutivo da doen&#231;a (4,12-15).     ]]></body>
<body><![CDATA[<br/>      <br/><b >A Import&#226;ncia da Interven&#231;&#227;o     Nutricional na ELA</b>     <br/>A     nutri&#231;&#227;o &#233; um factor de progn&#243;stico independente na sobrevida esperada da ELA,     j&#225; que a degrada&#231;&#227;o nutricional nestes doentes &#233; esperada mas, em algumas     formas, evit&#225;vel se abordada proactivamente (16,17).     <br/>Durante     a evolu&#231;&#227;o da doen&#231;a todos os m&#250;sculos da l&#237;ngua, l&#225;bios, palato, faringe e     laringe v&#227;o sendo gradualmente afectados, resultando num b&#243;lus alimentar     ]]></body>
<body><![CDATA[insuficiente. &#192; medida que a motilidade, for&#231;a e coordena&#231;&#227;o dos m&#250;sculos     orofaciais e l&#237;nguais diminuem, emergem problemas relacionados com a prepara&#231;&#227;o     oral, mastiga&#231;&#227;o e o transporte oral dos alimentos (3). Os membros superiores     acabar&#227;o tamb&#233;m por ser afectados, assim o doente perder&#225; a capacidade de se     movimentar, comprometendo a autonomia alimentar e o manejo da palamenta     tradicional (17). A progress&#227;o da disfagia causar&#225; a necessidade de alterar a     via de alimenta&#231;&#227;o, da via oral para a via ent&#233;rica optando por um dispositivo     de nutri&#231;&#227;o ent&#233;rica (4).      <br/>Sendo     assim, a interven&#231;&#227;o nutricional na ELA exigir&#225; um conjunto de procedimentos,     ]]></body>
<body><![CDATA[tais como: a adapta&#231;&#227;o da consist&#234;ncia dos alimentos, a adequa&#231;&#227;o da via de     alimenta&#231;&#227;o &#224; capacidade deglutiva do doente, o c&#225;lculo e programa&#231;&#227;o da     ingest&#227;o pela via ent&#233;rica, entre outros aspectos (16,17).      <br/><u> </u>     <br/><b >Planeamento da Interven&#231;&#227;o     Nutricional</b>     <br/>Maximizar     o conforto e prazer do doente, minimizando o mal-estar f&#237;sico e emocional     constitui o objectivo b&#225;sico na orienta&#231;&#227;o do apoio nutricional a prestar nas     diversas fases da doen&#231;a. Torna-se tamb&#233;m necess&#225;rio prevenir e tratar quadros     ]]></body>
<body><![CDATA[de desnutri&#231;&#227;o, agindo proactivamente do ponto de vista nutricional e evitando     assim uma degrada&#231;&#227;o nutricional desnecess&#225;ria nestes doentes. A escolha da     estrat&#233;gia nutricional mais apropriada a seguir para os doentes com ELA deve     basear-se num processo cont&#237;nuo de avalia&#231;&#227;o nutricional e monitoriza&#231;&#227;o do     aconselhamento prestado. Assim, numa primeira abordagem devem ser revistos     todos os dados da hist&#243;ria cl&#237;nica, os sintomas e discutida a sobrevida esperada.     Da avalia&#231;&#227;o nutricional devem constar os dados antropom&#233;tricos, os dados     laboratoriais, o exame f&#237;sico, a avalia&#231;&#227;o dos sintomas de impacto nutricional,     a realiza&#231;&#227;o da anamnese alimentar, a avalia&#231;&#227;o das altera&#231;&#245;es recentes na     ingest&#227;o alimentar e da atitude psicol&#243;gica face a alimenta&#231;&#227;o assim como a     ]]></body>
<body><![CDATA[avalia&#231;&#227;o do contexto social e familiar de suporte (18,19).     <br/>A     decis&#227;o sobre o suporte nutricional a instituir dever&#225; ser tomada no seio da     equipa multidisciplinar muitas vezes com o apoio de outros t&#233;cnicos, como por     exemplo o terapeuta da fala, ap&#243;s o processo de avalia&#231;&#227;o nutricional. O plano     nutricional institu&#237;do dever&#225; ser permanentemente monitorizado (18,19). Apesar     de todos os par&#226;metros de avalia&#231;&#227;o nutricional anteriormente citados serem     relevantes, ao longo da progress&#227;o da doen&#231;a e especialmente no per&#237;odo de fim     de vida, &#233; necess&#225;rio seleccion&#225;-los e estabelecer a sua pertin&#234;ncia ou     futilidade para os objectivos que se pretende cumprir no momento actual da vida     ]]></body>
<body><![CDATA[do doente (19).     <br/><u> </u>     <br/><b >Aconselhamento Alimentar no Controlo     da Disfagia</b>     <br/>A     disfagia &#233; um sintoma comum da ELA (1) que origina um elevado risco de     aspira&#231;&#227;o (1,17), desnutri&#231;&#227;o (1,4,14,17), perda de peso (1,4) e desidrata&#231;&#227;o     (1,14,16,20). Geralmente na ELA, a disfagia tem in&#237;cio com a dificuldade em     deglutir l&#237;quidos e, posteriormente, progride para os alimentos s&#243;lidos (16). O     controlo da disfagia envolve o aconselhamento alimentar (1), a modifica&#231;&#227;o da     ]]></body>
<body><![CDATA[consist&#234;ncia da dieta (1,16,17,20) e a utiliza&#231;&#227;o de estrat&#233;gias de alimenta&#231;&#227;o     seguras, muitas das vezes em colabora&#231;&#227;o com a avalia&#231;&#227;o de outros t&#233;cnicos,     tais como o terapeuta da fala (16).     <br/>Relativamente     aos s&#243;lidos, os alimentos macios e h&#250;midos constituem boas op&#231;&#245;es por serem     melhor tolerados. Devem ser escolhidos alimentos de elevada densidade cal&#243;rica     e nutricional e a utiliza&#231;&#227;o de espessantes em p&#243; poder&#225; permitir uma melhor     adequa&#231;&#227;o da consist&#234;ncia dos alimentos (17). Os l&#237;quidos s&#227;o melhor tolerados     quando s&#227;o frios e espessos, proporcionando uma passagem mais lenta pela     cavidade oral (17-19). As refei&#231;&#245;es devem ser planeadas seguindo os     ]]></body>
<body><![CDATA[pressupostos de variedade, equil&#237;brio e presen&#231;a de todos os grupos de     alimentos, e preparadas garantindo a homogeneiza&#231;&#227;o das mesmas. A utiliza&#231;&#227;o de     suplementos nutricionais poder&#225; ser &#250;til para complementar a ingest&#227;o     nutricional de base. A apresenta&#231;&#227;o do prato dever&#225; manter a atractividade     atrav&#233;s da mistura de alimentos de cores diferentes e utiliza&#231;&#227;o de formas. A     utiliza&#231;&#227;o de palamenta adaptada &#224;s dificuldades de mobilidade (talheres     ergon&#243;micos de cabo anat&#243;mico, suportes para talheres, prato para conserva&#231;&#227;o     do calor, ta&#231;as com ventosas, entre outros), poder&#225; constituir tamb&#233;m um factor     importante na optimiza&#231;&#227;o alimentar e na promo&#231;&#227;o de autonomia.      <br/>As     ]]></body>
<body><![CDATA[refei&#231;&#245;es dever&#227;o ser feitas em ambientes calmos, o doente dever&#225; ingerir os     alimentos devagar e em pequenas por&#231;&#245;es de cada vez e concentrar-se na     degluti&#231;&#227;o, alternando a ingest&#227;o de s&#243;lidos com l&#237;quidos, se adequado. O     planeamento do apoio para a toma das refei&#231;&#245;es dever&#225; ser tido em linha de conta     ao longo da evolu&#231;&#227;o da doen&#231;a (17).     <br/><u> </u>     <br/><b >Suporte Nutricional Ent&#233;rico</b>     <br/>Com     a progress&#227;o da doen&#231;a a alimenta&#231;&#227;o oral ser&#225; ineficiente, constituir&#225; um     risco e tornar-se-&#225; imposs&#237;vel. Assim, torna-se imprescind&#237;vel a programa&#231;&#227;o     ]]></body>
<body><![CDATA[proactiva da altera&#231;&#227;o da via de alimenta&#231;&#227;o de forma a evitar altera&#231;&#245;es     desnecess&#225;rias do estado nutricional, manter uma hidrata&#231;&#227;o adequada e     paralelamente constituir uma forma de administra&#231;&#227;o da terap&#234;utica (14,17,21).     A institui&#231;&#227;o deste tipo de suporte nutricional deve ser discutida     proactivamente com o doente antes de este manifestar uma disfagia severa,     evitando a degrada&#231;&#227;o do seu estado e aliviando o desconforto (4).     <br/>Na     ELA est&#225; preconizado que a nutri&#231;&#227;o ent&#233;rica seja realizada atrav&#233;s de Sonda     Nasog&#225;strica (SNG), Gastrostomia Percut&#226;nea Endosc&#243;pica (GPE) ou Gastrostomia     Radiologicamente Inserida (GRI) (1,4,20).      ]]></body>
<body><![CDATA[<br/>Como     medida tempor&#225;ria a SNG &#233; um procedimento &#250;til para manter os cuidados     alimentares e de hidrata&#231;&#227;o antes de ser colocada a GPE ou a GRI (4,6,12).     Apresenta como desvantagens o facto de limitar os movimentos, de interferir com     a auto-imagem, de ser desconfort&#225;vel e poder causar dor, ulcera&#231;&#227;o nasofaringea     ou aspira&#231;&#227;o (4).      <br/>A     GPE &#233; o dispositivo mais utilizado (20). S&#227;o crit&#233;rios de coloca&#231;&#227;o da GPE: a     morosidade das refei&#231;&#245;es (em cerca de 30 minutos), o momento em que as     tentativas para deglutir resultam em n&#225;useas/ v&#243;mitos, a incapacidade de     ]]></body>
<body><![CDATA[deglutir qualquer alimento, a altera&#231;&#227;o do peso com percentagem de peso perdido     superior a 10%, o &#237;ndice de massa corporal inferior a 18,5kg/m2 e a altera&#231;&#227;o     da fun&#231;&#227;o respirat&#243;ria mantendo uma Capacidade Vital For&#231;ada (CVF) superior a     50% (1,4,6,12,13,18,20,22,23). Recomenda-se a coloca&#231;&#227;o de GRI em doentes com     os mesmos crit&#233;rios supracitados mas com CVF inferior a 50%, por n&#227;o ser     necess&#225;rio administrar anestesia. Como desvantagens podem ocorrer dor, v&#243;mitos,     diarreia, obstipa&#231;&#227;o, hemorragia, forma&#231;&#227;o de f&#237;stula gastroc&#243;lica ou necrose     parietal (4).      <br/>Relativamente     aos esquemas de nutri&#231;&#227;o ent&#233;rica a utilizar, estes podem ser de uso exclusivo     ]]></body>
<body><![CDATA[de produtos comerciais, de uso exclusivo de alimentos liquefeitos ou de     combina&#231;&#227;o de produtos comerciais com alimentos liquefeitos. Os esquemas de     administra&#231;&#227;o mais frequentemente utilizados s&#227;o: o b&#243;lus de pequeno volume     v&#225;rias vezes ao dia, a administra&#231;&#227;o intermitente e a administra&#231;&#227;o cont&#237;nua     com ou sem pausa. A escolha do tipo de esquema de nutri&#231;&#227;o ent&#233;rica e do m&#233;todo     de administra&#231;&#227;o deve obedecer aos seguintes crit&#233;rios: avalia&#231;&#227;o cl&#237;nica,     prefer&#234;ncia do doente e valor atribu&#237;do a prepara&#231;&#245;es culin&#225;rias,     compatibilidade com os hor&#225;rios, grau de depend&#234;ncia e actividades realizadas     pelo doente, adequa&#231;&#227;o do volume e composi&#231;&#227;o das tomas, tendo em conta a     toler&#226;ncia gastrointestinal e reprodutibilidade ao n&#237;vel domicili&#225;rio (24). &#201;     ]]></body>
<body><![CDATA[tamb&#233;m importante que se respeite os desejos do doente relativamente ao volume,     &#224; hora e ao tipo de administra&#231;&#227;o sendo que, em fases mais avan&#231;adas, se a     comunica&#231;&#227;o estiver impossibilitada, a avalia&#231;&#227;o do res&#237;duo g&#225;strico constitui     um instrumento &#250;til (18,19).     <br/>&#192;     medida que a doen&#231;a progride, os doentes com ELA ir&#227;o experimentar um conjunto     de modifica&#231;&#245;es fisiol&#243;gicas que compreendem a lentifica&#231;&#227;o do tempo de     esvaziamento g&#225;strico e do perist&#225;ltismo, bem como altera&#231;&#245;es no processo     digestivo e de absor&#231;&#227;o intestinal. A redu&#231;&#227;o de volumes e a simplifica&#231;&#227;o do     tipo de esquemas nutricionais utilizados s&#227;o de extrema import&#226;ncia para a     ]]></body>
<body><![CDATA[melhoria/controlo da estase g&#225;strica e outras altera&#231;&#245;es. Eventualmente e em     fases finais da doen&#231;a se a nutri&#231;&#227;o ent&#233;rica deixar de melhorar a qualidade de     vida do doente, esta ao tornar-se f&#250;til, dever&#225; ser suspensa (24).     <br/><u> </u>     <br/><b >Abordagem Nutricional Centrada no     Doente e na Fam&#237;lia</b>     <br/>Proporcionar     o melhor acompanhamento nutricional poss&#237;vel aos doentes com ELA n&#227;o passa     apenas pela utiliza&#231;&#227;o de estrat&#233;gias no controlo da disfagia ou pela adapta&#231;&#227;o     a uma nova via de alimenta&#231;&#227;o. &#201; tamb&#233;m necess&#225;rio que o nutricionista tenha em     ]]></body>
<body><![CDATA[considera&#231;&#227;o todas as altera&#231;&#245;es que uma doen&#231;a t&#227;o incapacitante como a ELA     ir&#225; provocar na rotina alimentar tanto do doente como da sua fam&#237;lia e que seja     capaz de encontrar solu&#231;&#245;es e estrat&#233;gias que ajudem a tornar a alimenta&#231;&#227;o num     acto de prazer e conforto.      <br/>Os     doentes com ELA confrontam-se com in&#250;meras perdas ao n&#237;vel da alimenta&#231;&#227;o:     inicialmente a capacidade para se auto-alimentarem e de manejarem a palamenta,     e por &#250;ltimo, a incapacidade de deglutir e utilizar a via oral. Eventualmente,     a perda de apetite e a recusa alimentar poder&#227;o surgir como reflexo da     altera&#231;&#227;o do processo alimentar e/ou desconforto em torno deste (25-28). Assim,     ]]></body>
<body><![CDATA[caber&#225; ao nutricionista especificar a sua interven&#231;&#227;o para a ELA, no sentido de     discutir com o doente novas alternativas alimentares e esclarecer d&#250;vidas,     mostrando ao doente que apesar da disfagia &#233; poss&#237;vel obter prazer com os     alimentos de consist&#234;ncia alterada e usufruir das situa&#231;&#245;es sociais     proporcionadas pelas refei&#231;&#245;es. &#201; tamb&#233;m fundamental esclarecer que aquando da     mudan&#231;a da via de alimenta&#231;&#227;o &#233; tamb&#233;m poss&#237;vel usufruir das refei&#231;&#245;es em     ambientes de conviv&#234;ncia social.     <br/>No     entanto, a abordagem destes temas v&#234;-se perturbada pelas dificuldades de     comunica&#231;&#227;o dos doentes. Muito embora o trabalho do nutricionista se possa basear     ]]></body>
<body><![CDATA[na percep&#231;&#227;o e observa&#231;&#245;es da fam&#237;lia sobre h&#225;bitos e prefer&#234;ncias alimentares     do doente, existem aspectos sobre os quais s&#243; ele poder&#225; comunicar. Sendo     assim, torna-se bastante &#250;til que o nutricionista conhe&#231;a o funcionamento de     eventuais dispositivos de comunica&#231;&#227;o assistida e que seja criativo nas formas     de promover o di&#225;logo e personalizar a sua interven&#231;&#227;o.     <br/>A     ELA &#233; uma doen&#231;a que tornar&#225; o doente totalmente dependente e &#224; medida que a     doen&#231;a evolui, existem outros factores que condicionam a adapta&#231;&#227;o do doente a     uma nova realidade alimentar, tais como a idade, o sexo e o ambiente familiar.     No contexto familiar, as altera&#231;&#245;es alimentares impostas pela doen&#231;a, passam a     ]]></body>
<body><![CDATA[estar cada vez mais presentes na vida familiar j&#225; que &#233; necess&#225;rio preparar as     refei&#231;&#245;es com as especificidades necess&#225;rias (25-27). Assim, o plano alimentar     que o nutricionista elabora constitui um elemento orientador para alternativas     que v&#227;o o mais poss&#237;vel de encontro aos h&#225;bitos alimentares que se praticavam     at&#233; ent&#227;o. Tamb&#233;m as rotinas alimentares da fam&#237;lia poder&#227;o ser alteradas pelo     aumento de tarefas culin&#225;rias em torno dos cuidados ao doente. Assim, sempre     que poss&#237;vel, o aconselhamento alimentar prestado dever&#225; constituir um elemento     conciliador das necessidades nutricionais do doente e das rotinas alimentares     da fam&#237;lia. &#201; importante salientar que muitas vezes no seio da fam&#237;lia surgem     in&#250;meras quest&#245;es relativamente &#224; perda de peso e de apetite e tamb&#233;m &#224;     ]]></body>
<body><![CDATA[eventual recusa alimentar por parte do doente (26-29). Portanto, &#233; extremamente     importante explicar &#224; fam&#237;lia que existem outras fontes de degrada&#231;&#227;o corporal     que interferem com a auto-imagem, peso e apetite que em nada se correlacionam     com a alimenta&#231;&#227;o, mas que dependem da evolu&#231;&#227;o da doen&#231;a.      <br/>Chegado     o momento em que a doen&#231;a progride para um estado terminal em que h&#225; a     possibilidade de suspender a alimenta&#231;&#227;o, fam&#237;lias mal assistidas ou     acompanhadas poder&#227;o associar este acontecimento ao precipitar da morte. Assim,     nas rotinas de acompanhamento nutricional os processos de comunica&#231;&#227;o em torno     da verdade e do esclarecimento de d&#250;vidas e medos &#233; fundamental (30).</p>     ]]></body>
<body><![CDATA[<p><b >An&#225;lise Cr&#237;tica e Conclus&#245;es</b> <br/>Na ELA, a interven&#231;&#227;o nutricional dever&#225; contribuir para o bem-estar e conforto do doente, pelo que o seu planeamento dever&#225; passar por uma constante monitoriza&#231;&#227;o e adequa&#231;&#227;o de objectivos. Para que este planeamento v&#225; de encontro &#224;s reais necessidades dos doentes, o nutricionista deveria primeiramente compreender quais as expectativas e desejos do doente em rela&#231;&#227;o ao suporte nutricional e, posteriormente, conjugar esses desejos e expectativas com o seu aconselhamento nutricional. No entanto, a literatura existente para a ELA n&#227;o contempla ainda estas tem&#225;ticas. <br/>A disfagia representa o sintoma que mais altera&#231;&#245;es provoca ao n&#237;vel da alimenta&#231;&#227;o, pelo que, exige a adapta&#231;&#227;o do tipo de dieta. Quando a disfagia progride, a altera&#231;&#227;o da via de alimenta&#231;&#227;o constituir&#225; certamente uma altera&#231;&#227;o profunda dos h&#225;bitos alimentares praticados at&#233; ent&#227;o. No entanto, quer ao n&#237;vel do controlo da disfagia quer ao n&#237;vel do suporte nutricional ent&#233;rico, parece verificar-se uma grande escassez de literatura e de estudos no que diz respeito aos principais medos e expectativas que os doentes apresentam perante as sucessivas altera&#231;&#245;es na alimenta&#231;&#227;o e, que em muito ajudaria o nutricionista a tornar a sua interven&#231;&#227;o mais completa. <br/>A abordagem nutricional centrada no doente e na fam&#237;lia &#233; indissoci&#225;vel da restante interven&#231;&#227;o nutricional, j&#225; que quando realizada constitui um elemento fundamental em todo o acompanhamento e na prepara&#231;&#227;o do doente para o percurso que ele, a fam&#237;lia e a alimenta&#231;&#227;o ir&#227;o fazer em conjunto desde o in&#237;cio da doen&#231;a at&#233; ao fim de vida. Neste tipo de abordagem existe ainda muita car&#234;ncia de estudos que avaliem a forma como o doente e a fam&#237;lia percepcionam e sentem as altera&#231;&#245;es alimentares no decorrer da doen&#231;a. <br/>A ELA &#233; uma doen&#231;a que exigir&#225; cuidados nutricionais em fim de vida. Assim, e uma vez que em Portugal existem muito poucos nutricionistas com forma&#231;&#227;o nesta &#225;rea, seria importante que estes aprofundassem os seus conhecimentos no que diz respeito ao suporte nutricional em cuidados paliativos. <br/>Assim, conclui-se que na ELA as principais &#225;reas de interven&#231;&#227;o do nutricionista s&#227;o: o planeamento da sua interven&#231;&#227;o, o aconselhamento alimentar no controlo da disfagia, o suporte nutricional ent&#233;rico e a abordagem centrada no doente e na fam&#237;lia.</p>     <p><b >Agradecimentos</b> <br/>&#192; D.&#170; Maria Pinho Barros por ter ajudado a despertar em mim o interesse pelo papel da nutri&#231;&#227;o na ELA e nos cuidados continuados e paliativos.</p>     <p>&nbsp;</p>     <!-- ref --><p><b >Refer&#234;ncias Bibliogr&#225;ficas</b> <br/>1. Oliveira ASB, Pereira RDB. Amyotrophic lateral sclerosis (ALS) &#8211; Three Letters That Change The People&#180;s Life &#8211; Forever. Arquives of Neuropsyquiatrics 2009; 67: 750-782 <br/>2.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1716202&pid=S2182-7230201200030000800001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --> Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet Journal of Rare Diseases 2009; 4: 3 <br/>3.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1716203&pid=S2182-7230201200030000800002&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --> Sathasivam S. Motor neurone disease: clinical features, diagnosis, diagnostic pitfalls and prognostic markers. Singapore Medical Journal 2010; 51: 367-373 <br/>4.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1716204&pid=S2182-7230201200030000800003&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --> Radunovic A, Mitsumoto H, Leigh PN. Clinical care of patients with amyotrophic lateral sclerosis. Lancet Neurology 2007; 6: 913-925 <br/>5.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1716205&pid=S2182-7230201200030000800004&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --> Musar&#242; A. State of the art and the dark side of amyotrophic lateral sclerosis. World Journal of Biological Chemistry 2010; 1: 62-68 <br/>6.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1716206&pid=S2182-7230201200030000800005&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --> Moore MC, McDermott CJ, Shaw PJ. Clinical aspects of motor neurone disease. Medicine 2008; 36: 640-645 <br/>7.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1716207&pid=S2182-7230201200030000800006&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --> Shoesmith CL, Strong MJ. Amyotrophic lateral sclerosis update for family physicians. Canadian Family Physician 2006; 52: 1563-1569 <br/>8.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1716208&pid=S2182-7230201200030000800007&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --> Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zoing MC. Amyotrophic lateral sclerosis. Lancet 2011; 377: 942-955 <br/>9.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1716209&pid=S2182-7230201200030000800008&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --> Cameron A, Rosenfeld J. Nutritional issues and supplements in amyotrophic lateral sclerosis and other neurodegenerative disorders. Current Opinion in Clinical Nutrition and Metabolic Care 2002; 5: 631-643 <br/>10.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1716210&pid=S2182-7230201200030000800009&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --> Zoccolella S, Santamato A, Lamberti P. Current and emerging treatments for amyotrophic lateral sclerosis. Neuropsychiatric Disease and Treatment 2009; 5: 557-595 <br/>11.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1716211&pid=S2182-7230201200030000800010&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --> Barber SC, Shaw PJ. Oxidative Stress in ALS: Key role in motor neuron injury and therapeutic target. Free Radical Biological Medicine 2010; 48: 629-641 <br/>12.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1716212&pid=S2182-7230201200030000800011&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --> Simmons Z. Management Strategies for Patients With Amyotrophic Lateral Sclerosis From Diagnosis Through Death. The Neurologist 2005; 11: 257-270 <br/>13.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1716213&pid=S2182-7230201200030000800012&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --> McDermott CJ, Shaw PJ. Diagnosis and management of neurone disease. British Medical Journal 2008; 336: 658-662 <br/>14.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1716214&pid=S2182-7230201200030000800013&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --> Pontes RT, Orsini M, de Freitas MRG, Antonioli RS, Nascimento OJM. Altera&#231;&#245;es da fona&#231;&#227;o e degluti&#231;&#227;o na Esclerose Lateral Amiotr&#243;fica: Revis&#227;o de Literatura. Revista Neuroci&#234;ncias 2010; 18: 69-73 <br/>15.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1716215&pid=S2182-7230201200030000800014&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --> Mitsumoto H, Rabkin JG. Palliative Care for Patients With Amyotrophic Lateral Sclerosis - &#8220;Prepare for the Worst and Hope for the Best&#8221;. Journal of American Medical Association 2007; 298: 207-216 <br/>16.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1716216&pid=S2182-7230201200030000800015&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --> Heffernan C, Jenkisnon C, Holes T, Feder G, Kupfer R, Leigh PN, McGowan S, Rio A, Sidhu P. Nutritional management in MND/ALS patients: an evidence based review. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2004; 5: 72-83 <br/>17.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1716217&pid=S2182-7230201200030000800016&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --> K&#252;hnlein P, Gdynia HJ, Sperfeld AD, Lindener-Pfeghar BL, Ludolph AC, Prosiegel M, Riecker A. Diagnosis and treatment of bulbar symptoms in amyotrophic lateral sclerosis. Nature Clinical Practice Neurology 2008; 4: 366-374 <br/>18.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1716218&pid=S2182-7230201200030000800017&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --> Squires N. Dysphagia management for progressive neurological conditions. Nursing Standard 2006; 20: 53-57  <br/>19.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1716219&pid=S2182-7230201200030000800018&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --> Bozzetti F. Amadori D, Bruera E, Cozzglio l, Corli O, Filiberti A, Rapin CH, Neuenschwander H, Aoun M, Ricci SB, De Conno F, Doci R, Garrone M, Gentilini M, Lery N, Mantell M, Sheldon-Collins R, Trompino G. Guidelines on Artificial Nutrition Versus Hydration in Terminal Cancer Patients. Nutrition 1996; 12: 163-167 <br/>20.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1716220&pid=S2182-7230201200030000800019&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --> Tanasescu R, Tiemeanu M, Luca D, Cojocaru I, Frasineanu A, Oprisan A, Hristea A, Ene A, Anghel D, Nicolau A. Management Strategies in Amyotrophic Lateral Sclerosis. Romanian Journal of Neurology 2007; 4: 147-152 <br/>21.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1716221&pid=S2182-7230201200030000800020&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --> Carlesi C, Pasquali L, Piazza S, Gerfo AL, Lenco EC, Alessi R, Fornai F, Siciliano G. Strategies for clinical approach to neurodegeneration in amyotrophic lateral sclerosis. Archives Italienes de Biologie 2011; 149: 151-167 <br/>22.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1716222&pid=S2182-7230201200030000800021&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --> Capozza CM, Sousa AM. Preventing malnutrition in the home care client. Caring 1994; 13: 68-71 <br/>23.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1716223&pid=S2182-7230201200030000800022&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --> Boyd KJ, Beeken L. Tube feeding in palliative care: benefits and problems. Palliative Medicine 1994; 8: 156-158 <br/>24.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1716224&pid=S2182-7230201200030000800023&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --> Byock IR. Patient refusal of nutrition and hydration: walking the ever fine line. The American Journal of Hospice and Palliative Care 1995; 1: 8-13 <br/>25.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1716225&pid=S2182-7230201200030000800024&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --> Hopkins K. Food for life, love and hope: an exemplar of the philosophy of palliative care in action. Proceedings of the Nutrition Society 2004; 63: 427-429 <br/>26.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1716226&pid=S2182-7230201200030000800025&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --> Huges N, Neal RD. Adults with terminal illness: a literature review of their needs and wishes for food. Journal of Advanced Nursing 2000; 32: 1101-1107 <br/>27.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1716227&pid=S2182-7230201200030000800026&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --> Evans BC, Crogan NL, Shultz JA. The meaning of mealtimes: Connection to the social world of the nursing home. Journal of Gerontological Nursing 2005; 31: 11-17 <br/>28.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1716228&pid=S2182-7230201200030000800027&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --> McClement S, Degner l, Harlos M. Family responses to Declining Intake and weight loss: a Terminally ill Relative. Part 1: Fighting Back, Journal of Palliative Medicine 2003; 20: 93-100 <br/>29.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1716229&pid=S2182-7230201200030000800028&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --> Souter J. Loss of appetite: a poetic exploration of cancer patients&#8217; and their carers&#8217; experiences. International Journal of Palliative Nursing 2005; 11: 524-532 <br/>30.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1716230&pid=S2182-7230201200030000800029&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --> Slomka J. Withholding nutrition at the end of life: Clinical and ethical issues. Cleveland Clinic Journal of Medicine 2003; 70: 548-552&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1716231&pid=S2182-7230201200030000800030&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p>&nbsp;</p>     <p><b ><a href="#topc0">Endere&#231;o para correspond&#234;ncia</a><a name="c0"></a></b> <br/>C&#237;ntia Reis <br/>Rua Dr. Eduardo Torres, n.&#186; 1785, 4.&#186; B, <br/>4460-301 Senhora da Hora <br/><a href="mailto:cintia.vp.reis@gmail.com">cintia.vp.reis@gmail.com</a> </p>  <br/>Recebido a 30 de Dezembro de 2011 <br/>Aceite a 14 de Setembro de 2012 <br/>  <br/>       ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[ASB]]></given-names>
</name>
<name>
<surname><![CDATA[Pereira]]></surname>
<given-names><![CDATA[RDB]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Amyotrophic lateral sclerosis (ALS) - Three Letters That Change The People´s Life - Forever]]></article-title>
<source><![CDATA[Arquives of Neuropsyquiatrics]]></source>
<year>2009</year>
<volume>67</volume>
<page-range>750-782</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wijesekera]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Leigh]]></surname>
<given-names><![CDATA[PN]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Amyotrophic lateral sclerosis]]></article-title>
<source><![CDATA[Orphanet Journal of Rare Diseases]]></source>
<year>2009</year>
<volume>4</volume>
<page-range>3</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sathasivam]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Motor neurone disease: clinical features, diagnosis, diagnostic pitfalls and prognostic markers]]></article-title>
<source><![CDATA[Singapore Medical Journal]]></source>
<year>2010</year>
<volume>51</volume>
<page-range>367-373</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Radunovic]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mitsumoto]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Leigh]]></surname>
<given-names><![CDATA[PN]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Clinical care of patients with amyotrophic lateral sclerosis]]></article-title>
<source><![CDATA[Lancet Neurology]]></source>
<year>2007</year>
<volume>6</volume>
<page-range>913-925</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Musarò]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[State of the art and the dark side of amyotrophic lateral sclerosis]]></article-title>
<source><![CDATA[World Journal of Biological Chemistry]]></source>
<year>2010</year>
<volume>1</volume>
<page-range>62-68</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moore]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[McDermott]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Shaw]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Clinical aspects of motor neurone disease]]></article-title>
<source><![CDATA[Medicine]]></source>
<year>2008</year>
<volume>36</volume>
<page-range>640-645</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shoesmith]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Strong]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Amyotrophic lateral sclerosis update for family physicians]]></article-title>
<source><![CDATA[Canadian Family Physician]]></source>
<year>2006</year>
<volume>52</volume>
<page-range>1563-1569</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kiernan]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Vucic]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cheah]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
<name>
<surname><![CDATA[Turner]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Eisen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hardiman]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Burrell]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Zoing]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Amyotrophic lateral sclerosis]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2011</year>
<volume>377</volume>
<page-range>942-955</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cameron]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenfeld]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Nutritional issues and supplements in amyotrophic lateral sclerosis and other neurodegenerative disorders]]></article-title>
<source><![CDATA[Current Opinion in Clinical Nutrition and Metabolic Care]]></source>
<year>2002</year>
<volume>5</volume>
<page-range>631-643</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zoccolella]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Santamato]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lamberti]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Current and emerging treatments for amyotrophic lateral sclerosis]]></article-title>
<source><![CDATA[Neuropsychiatric Disease and Treatment]]></source>
<year>2009</year>
<volume>5</volume>
<page-range>557-595</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barber]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Shaw]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Oxidative Stress in ALS: Key role in motor neuron injury and therapeutic target]]></article-title>
<source><![CDATA[Free Radical Biological Medicine]]></source>
<year>2010</year>
<volume>48</volume>
<page-range>629-641</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simmons]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Management Strategies for Patients With Amyotrophic Lateral Sclerosis From Diagnosis Through Death]]></article-title>
<source><![CDATA[The Neurologist]]></source>
<year>2005</year>
<volume>11</volume>
<page-range>257-270</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McDermott]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Shaw]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Diagnosis and management of neurone disease]]></article-title>
<source><![CDATA[British Medical Journal]]></source>
<year>2008</year>
<volume>336</volume>
<page-range>658-662</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pontes]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
<name>
<surname><![CDATA[Orsini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[de Freitas]]></surname>
<given-names><![CDATA[MRG]]></given-names>
</name>
<name>
<surname><![CDATA[Antonioli]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Nascimento]]></surname>
<given-names><![CDATA[OJM]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Alterações da fonação e deglutição na Esclerose Lateral Amiotrófica: Revisão de Literatura]]></article-title>
<source><![CDATA[Revista Neurociências]]></source>
<year>2010</year>
<volume>18</volume>
<page-range>69-73</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mitsumoto]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Rabkin]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Palliative Care for Patients With Amyotrophic Lateral Sclerosis - "Prepare for the Worst and Hope for the Best": Journal of American Medical]]></article-title>
<source><![CDATA[Association]]></source>
<year>2007</year>
<volume>298</volume>
<page-range>207-216</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heffernan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Jenkisnon]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Holes]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Feder]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kupfer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Leigh]]></surname>
<given-names><![CDATA[PN]]></given-names>
</name>
<name>
<surname><![CDATA[McGowan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sidhu]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Nutritional management in MND/ALS patients: an evidence based review]]></article-title>
<source><![CDATA[Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders]]></source>
<year>2004</year>
<volume>5</volume>
<page-range>72-83</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kühnlein]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gdynia]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sperfeld]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Lindener-Pfeghar]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
<name>
<surname><![CDATA[Ludolph]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Prosiegel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Riecker]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Diagnosis and treatment of bulbar symptoms in amyotrophic lateral sclerosis]]></article-title>
<source><![CDATA[Nature Clinical Practice Neurology]]></source>
<year>2008</year>
<volume>4</volume>
<page-range>366-374</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Squires]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Dysphagia management for progressive neurological conditions]]></article-title>
<source><![CDATA[Nursing Standard]]></source>
<year>2006</year>
<volume>20</volume>
<page-range>53-57</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bozzetti]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Amadori D, Bruera E, Cozzglio l, Corli O, Filiberti A, Rapin CH, Neuenschwander H, Aoun M, Ricci SB, De Conno F, Doci R, Garrone M, Gentilini M, Lery N, Mantell M, Sheldon-Collins R, Trompino G: Guidelines on Artificial Nutrition Versus Hydration in Terminal Cancer Patients]]></article-title>
<source><![CDATA[Nutrition]]></source>
<year>1996</year>
<volume>12</volume>
<page-range>163-167</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tanasescu]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Tiemeanu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Luca]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Cojocaru]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Frasineanu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Oprisan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hristea]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ene]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Anghel]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Nicolau]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Management Strategies in Amyotrophic Lateral Sclerosis]]></article-title>
<source><![CDATA[Romanian Journal of Neurology]]></source>
<year>2007</year>
<volume>4</volume>
<page-range>147-152</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carlesi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Pasquali]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Piazza]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gerfo]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Lenco]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[Alessi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Fornai]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Siciliano]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Strategies for clinical approach to neurodegeneration in amyotrophic lateral sclerosis]]></article-title>
<source><![CDATA[Archives Italienes de Biologie]]></source>
<year>2011</year>
<volume>149</volume>
<page-range>151-167</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Capozza]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Sousa]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Preventing malnutrition in the home care client]]></article-title>
<source><![CDATA[Caring]]></source>
<year>1994</year>
<volume>13</volume>
<page-range>68-71</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boyd]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Beeken]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Tube feeding in palliative care: benefits and problems]]></article-title>
<source><![CDATA[Palliative Medicine]]></source>
<year>1994</year>
<volume>8</volume>
<page-range>156-158</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Byock]]></surname>
<given-names><![CDATA[IR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Patient refusal of nutrition and hydration: walking the ever fine line]]></article-title>
<source><![CDATA[The American Journal of Hospice and Palliative Care]]></source>
<year>1995</year>
<volume>1</volume>
<page-range>8-13</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hopkins]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Food for life, love and hope: an exemplar of the philosophy of palliative care in action]]></article-title>
<source><![CDATA[Proceedings of the Nutrition Society]]></source>
<year>2004</year>
<volume>63</volume>
<page-range>427-429</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huges]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Neal]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Adults with terminal illness: a literature review of their needs and wishes for food]]></article-title>
<source><![CDATA[Journal of Advanced Nursing]]></source>
<year>2000</year>
<volume>32</volume>
<page-range>1101-1107</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
<name>
<surname><![CDATA[Crogan]]></surname>
<given-names><![CDATA[NL]]></given-names>
</name>
<name>
<surname><![CDATA[Shultz]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The meaning of mealtimes: Connection to the social world of the nursing home]]></article-title>
<source><![CDATA[Journal of Gerontological Nursing]]></source>
<year>2005</year>
<volume>31</volume>
<page-range>11-17</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McClement]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<collab>Degner l.Harlos M</collab>
<article-title xml:lang="en"><![CDATA[Family responses to Declining Intake and weight loss: a Terminally ill Relative]]></article-title>
<source><![CDATA[Part 1: Fighting Back, Journal of Palliative Medicine]]></source>
<year>2003</year>
<volume>20</volume>
<page-range>93-100</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Souter]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Loss of appetite: a poetic exploration of cancer patients' and their carers' experiences]]></article-title>
<source><![CDATA[International Journal of Palliative Nursing]]></source>
<year>2005</year>
<volume>11</volume>
<page-range>524-532</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Slomka]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Withholding nutrition at the end of life: Clinical and ethical issues]]></article-title>
<source><![CDATA[Cleveland Clinic Journal of Medicine]]></source>
<year>2003</year>
<volume>70</volume>
<page-range>548-552</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
